Corapharm Deal Offers South-East Europe Opportunity For mAbxience
Fresenius-Controlled Spanish Developer Agrees Another Biosimilars Alliance
Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.
